#66 Survival of PARP inhibitor (PARPi) naïve ovarian cancer patients with a BRCA-mutation receiving maintenance olaparib after chemotherapy for first recurrence. An exploratory analysis of the solo2/engot-ov21 trial
作者
Jonathan A. Ledermann,Isabelle Ray‐Coquard,Richard T. Penson,Chee Khoon Lee,Amit M. Oza,Jacob Korach,Núria Laínez,Giovanni Scambia,Val Gebski,Nicoletta Colombo,Julia Welz,Keiichi Fujiwara,Elizabeth Lowe,Éric Pujade-Lauraine